达托霉素生物合成研究进展及临床研究  

Progress in Research of Biosynthesis of Daptomycin and Its Clinical Research

作　　者：韩培[1] 陈继业[1] 王岩[1] 陈少欣[1] 

机构地区：[1]中国医药工业研究总院上海医药工业研究院,上海200040

出　　处：《中国医药工业杂志》2011年第6期466-471,共6页Chinese Journal of Pharmaceuticals

基　　金：国家"重大新药创新"科技重大专项(2009ZX09301-007)

摘　　要：随着高致病耐药菌的不断出现,临床上对新型抗生素的需要变得十分迫切,达托霉素的上市使得环脂肽类化合物成为抗生素研发的热点之一。本文综述了达托霉素的生物合成基因簇、生物合成途径以及基于组合生物合成原理的达托霉素结构改造工作,为进一步利用基因工程手段来合成新的达托霉素衍生物提供理论依据。同时也简单介绍了达托霉素的临床研究进展。With the continual emergence of highly pathogenic drug-resistant bacteria,the clinical need for new antibiotics is becoming urgent.The marketing of daptomycin makes the cyclic lipopeptide compounds to be a hotspot for research and development of antibiotics.This review focuses on the progress of daptomycin gene cluster,biosynthesis pathway and structure modification of daptomycin by combinatorial biosynthesis.These would provide a theoretical basis for the biosynthesis of new daptomycin derivatives by genetic engineering.In addition,the clinical development of daptomycin is also presented briefly.

关 键 词：达托霉素 生物合成 组合生物合成 临床应用 综述 

分 类 号：R9[医药卫生—药学]